Such a shift in the Treg/CD8+ ratio is critical for enhancing anti-tumor immune responses, particularly in CMS4 CRC tumors where T cell dysfunction is a hallmark of the immunosuppressive microenvironment (12, 79). The gene discussed is CD8A; the disease is neoplasm.